Latest Merrimack Pharmaceuticals Inc. Stories
MM-398 in Combination with 5-FU and Leucovorin Provides New Treatment Option for Patients Previously Treated with Gemcitabine MANHATTAN BEACH, Calif., May 1, 2014 /PRNewswire/ -- The Pancreatic Cancer Action Network is pleased to announce that today Merrimack Pharmaceuticals, Inc., (Merrimack) reported a 1.9 month improvement in survival for patients treated with the combination of its drug, MM-398, with 5-fluorouracil (5-FU) and leucovorin. According to Merrimack, the NAPOLI-1...
- A spider.
- Figuratively, a peevish, testy, ill-natured person.